Lynparza Indications/Uses

Ovarian cancer: Lynparza is indicated as monotherapy for the: maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy; maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.
Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.
Breast cancer: Lynparza is indicated for the adjuvant treatment of adult patients with germline BRCA-mutated HER2 negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy (see Dosage & Administration and Pharmacology: Pharmacodynamics under Actions).
Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the neoadjuvant, adjuvant or metastatic setting unless patients were not suitable for these treatments (see Pharmacology: Pharmacodynamics under Actions).
Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
Pancreatic cancer: Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
Prostate cancer: Lynparza is indicated: as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castration- resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (e.g. abiraterone or enzalutamide); in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).